drugset / Trial / NCT00888862
Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Phase 3
Unknown
90 enrolled
Hamilton Health Sciences Corporation
McMaster University · collabSt. Joseph's Healthcare Hamilton · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to characterize a range of brain activation symptoms associated with depression and response to treatment in midlife men and women with MDD, using MRI and functional MRI. Moreover, in the female sub-group, the investigators will examine whether these brain activation symptoms are related to menopausal symptoms (i.e., hot flashes and night sweats). Also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.
Timeline
- Start
- 2009-06
- Primary completion
- 2012-06
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desvenlafaxine | Other / unclassified | 50 mg | — |
| Subject | Desvenlafaxine | Other / unclassified | 100 mg | — |